These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

248 related articles for article (PubMed ID: 22407480)

  • 1. An industrial perspective on contemporary applications of PBPK models in drug discovery and development.
    Smith BJ
    Biopharm Drug Dispos; 2012 Mar; 33(2):53-4. PubMed ID: 22407480
    [No Abstract]   [Full Text] [Related]  

  • 2. Physiologically based pharmacokinetic (PBPK) modeling: it is here to stay!
    Rostami-Hodjegan A; Tamai I; Pang KS
    Biopharm Drug Dispos; 2012 Mar; 33(2):47-50. PubMed ID: 22351594
    [No Abstract]   [Full Text] [Related]  

  • 3. Physiologically based pharmacokinetic modeling in drug discovery and development: a pharmaceutical industry perspective.
    Jones HM; Chen Y; Gibson C; Heimbach T; Parrott N; Peters SA; Snoeys J; Upreti VV; Zheng M; Hall SD
    Clin Pharmacol Ther; 2015 Mar; 97(3):247-62. PubMed ID: 25670209
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The role of discovery DMPK scientists in industry: where do we go from here?
    Moriwaki T
    Drug Metab Pharmacokinet; 2012; 27(2):169-70. PubMed ID: 22531680
    [No Abstract]   [Full Text] [Related]  

  • 5. Drug discovery in the next decade: innovation needed ASAP.
    Bennani YL
    Drug Discov Today; 2011 Sep; 16(17-18):779-92. PubMed ID: 21704185
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Application of IVIVE and PBPK modeling in prospective prediction of clinical pharmacokinetics: strategy and approach during the drug discovery phase with four case studies.
    Chen Y; Jin JY; Mukadam S; Malhi V; Kenny JR
    Biopharm Drug Dispos; 2012 Mar; 33(2):85-98. PubMed ID: 22228214
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Virtual drug discovery with the rise of Chinese CROs.
    Zhang MQ
    Drug Discov Today; 2010 Sep; 15(17-18):693-7. PubMed ID: 20685343
    [No Abstract]   [Full Text] [Related]  

  • 8. Developing pharmacogenetic evidence throughout clinical development.
    Burns DK
    Clin Pharmacol Ther; 2010 Dec; 88(6):867-70. PubMed ID: 20981004
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The long march of antisense.
    Jones D
    Nat Rev Drug Discov; 2011 Jun; 10(6):401-2. PubMed ID: 21629279
    [No Abstract]   [Full Text] [Related]  

  • 10. 2011 in reflection.
    Mullard A
    Nat Rev Drug Discov; 2012 Jan; 11(1):6-8. PubMed ID: 22212664
    [No Abstract]   [Full Text] [Related]  

  • 11. The future is much closer collaboration between the pharmaceutical industry and academic medical centers.
    Vallance P; Williams P; Dollery C
    Clin Pharmacol Ther; 2010 May; 87(5):525-7. PubMed ID: 20407455
    [No Abstract]   [Full Text] [Related]  

  • 12. Partnering for therapeutics discovery.
    Colvis CM; Devaney S; Brady LS; Hudson KL
    Clin Pharmacol Ther; 2013 Jan; 93(1):24-5. PubMed ID: 23187876
    [No Abstract]   [Full Text] [Related]  

  • 13. From preclinical to human--prediction of oral absorption and drug-drug interaction potential using physiologically based pharmacokinetic (PBPK) modeling approach in an industrial setting: a workflow by using case example.
    Sinha VK; Snoeys J; Osselaer NV; Peer AV; Mackie C; Heald D
    Biopharm Drug Dispos; 2012 Mar; 33(2):111-21. PubMed ID: 22383166
    [TBL] [Abstract][Full Text] [Related]  

  • 14. How informatics can potentiate precompetitive open-source collaboration to jump-start drug discovery and development.
    Perakslis ED; Van Dam J; Szalma S
    Clin Pharmacol Ther; 2010 May; 87(5):614-6. PubMed ID: 20376001
    [No Abstract]   [Full Text] [Related]  

  • 15. Modern phenotypic drug discovery is a viable, neoclassic pharma strategy.
    Lee JA; Uhlik MT; Moxham CM; Tomandl D; Sall DJ
    J Med Chem; 2012 May; 55(10):4527-38. PubMed ID: 22409666
    [No Abstract]   [Full Text] [Related]  

  • 16. Could pharma open its drug freezers?
    Mullard A
    Nat Rev Drug Discov; 2011 Jun; 10(6):399-400. PubMed ID: 21629278
    [No Abstract]   [Full Text] [Related]  

  • 17. The risky business of drug development in neurology.
    Craven R
    Lancet Neurol; 2011 Feb; 10(2):116-7. PubMed ID: 21256451
    [No Abstract]   [Full Text] [Related]  

  • 18. Picking up the pieces with FBDD or FADD: invest early for future success.
    Whittaker M
    Drug Discov Today; 2009 Jul; 14(13-14):623-4. PubMed ID: 19486947
    [No Abstract]   [Full Text] [Related]  

  • 19. The role of discovery DMPK scientists in industry: where do we go from here?
    Moriwaki T
    Drug Metab Pharmacokinet; 2012; 27(2):169-70. PubMed ID: 22666880
    [No Abstract]   [Full Text] [Related]  

  • 20. Society for Biomolecular Sciences--15th Annual Conference. Bioassay and technology innovation: 15 years of shaping drug discovery. 26-30 April 2009, Lille, France.
    Napper AD
    IDrugs; 2009 Jun; 12(6):363-5. PubMed ID: 19517316
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 13.